Biocon Ltd 2025 SR
The report details Biocon Limited's sustainability performance for FY 2024-25, focusing on its Generics and Biosimilars businesses. Key highlights include a 29% reduction in Scope 1 and 2 emissions against a FY 20 baseline and achieving 89% circularity in waste management. The company maintained a 'B' score in CDP Climate Change and improved its EcoVadis score to 77, earning a Gold rating. Social initiatives reached over 15.4 million patients with low-cost access to medicines. The report also outlines progress in water stewardship, achieving an 18% reduction in freshwater consumption.
Company: Biocon Ltd
Sector: Health Care
Country: India
Year: 2025
Type: SR
Pages: 100
Biocon Ltd
Brsr And ESG Data Book
The report details Biocon Limited's sustainability performance for FY 2024-25, focusing on its Generics and Biosimilars businesses. Key highlights include a 29% reduction in Scope 1 and 2 emissions against a FY 20 baseline and achieving 89% circularity in waste management. The company maintained a 'B' score in CDP Climate Change and improved its EcoVadis score to 77, earning a Gold rating. Social initiatives reached over 15.4 million patients with low-cost access to medicines. The report also outlines progress in water stewardship, achieving an 18% reduction in freshwater consumption.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Published
Jul 15, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees